TransMedics Inc. drummed up $3.57 million from 13 unidentified investors in another debt offering, according to a filing with the federal Securities and Exchange Commission.
The Andover-based firm is developing a system to keep organs viable outside the body until they can be transplanted. It’s got CE Mark approval for the system in the European Union and is undergoing clinical trials for use in heart transplants in the U.S.
The debt sales is the latest round of financing for TransMedics, which says it’s raised $90 million in venture-capital backing from 3i Group, Alta Partners, CB Health Ventures, Flagship Ventures, JP Morgan, Posco BioVentures, Sagamore Bioventures, Sherbrooke Capital, Tudor Investment Corp. and VantagePoint Venture Partners. The latest round, a $3.62 million offering, follows a $2.5 million round in July.
Calls to TransMedics seeking more details on its plans for the cash infusion were not immediately returned.